Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05940844
Other study ID # OB-002-101
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date January 2024
Est. completion date August 2025

Study information

Verified date July 2023
Source Orion Biotechnology Polska Sp. z o.o.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.


Description:

The dose escalation will use a conventional 3+3 approach, at a minimum of four planned dose levels (0.25, 0.5, 1.0, and 1.5 mg/kg), to establish a maximum tolerated dose (MTD). Additional dose levels may be investigated if PK, pharmacodynamic (PD), safety, and efficacy data indicate higher dose levels may be appropriate. The first patient - sentinel patient - at each dose level will be observed for three days before additional patients can be dosed within the same dose level. The patients will be dosed once weekly (Days 1, 8, 15, and 22) over a 4-week treatment cycle with a 28-day dose-limiting toxicity (DLT) observation period. After a full cohort has completed Day 28 assessments there will be a pause for safety evaluation conducted by the Safety Monitoring Committee (SMC). Once safety data have been reviewed, the SMC will make their recommendations to Orion who will decide whether to proceed to dosing the next dose cohort. Screening may continue during the SMC pause. Once all patients in the highest planned cohort (1.5 mg/kg OB 002) have completed Day 28 assessments, safety, PK, receptor occupancy (RO), and tolerability data will be reviewed to determine which dose level should be expanded or whether an additional dose level is needed. The expanded cohort will enrol 6 patients at the identified dose level. Patients may remain on treatment until disease progression with a follow-up (FU) period of up to 12 months. All adverse events (AEs) and non-invasive tumor assessments will be documented throughout the FU period to characterize the objective response rate (ORR) and, progression-free survival (PFS). Patients that do not complete the DLT observation period for non-DLT reasons will be replaced


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 36
Est. completion date August 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Written informed consent. 2. Patients at least 18 years of age on the day of providing consent. 3. Patients with accessible metastatic lesions for repetitive biopsy retrieval. 4. Patients with histologically or cytologically confirmed metastatic colorectal, pancreatic, gastric, breast, or urothelial tumors who have progressed or were intolerant after two or more regimens and for whom no standard of care or curative therapy options are available. 5. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 within 7 days of the start of treatment 6. Patients with evaluable and measurable lesions as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 7. Patients with adequate organ function at the time of enrollment as defined below: 1. Neutrophil count =1500/mm3 2. Platelet count =7.5 × 105/mm3 3. Hemoglobin >9.0g/dL (transfusion >2 weeks before testing permitted) 4. Aspartate transaminase (AST), alanine transaminase (ALT) =2.5 × the upper limit of normal (ULN) (=5-times in patients with liver metastasis) 5. Total bilirubin =1.5 × ULN 6. Creatinine clearance >60 mL (determined by Cockcroft-Gault Equation) 7. International normalized ratio (INR) =1.5 × ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) 8. In women with the potential for pregnancy (including patients with amenorrhea due to medical reasons, such as chemical menopause), after consenting to the study, the patient must agree to use contraception from enrollment and for at least 12 weeks after taking the final dose of the investigational drug. Women with the potential for pregnancy include those who have begun menstruation, who have not undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, and who have not gone through menopause. Menopause is defined as the consecutive absence of menstrual periods for =12 months. Total abstinence is an acceptable mode of contraception. 9. In the case of men, the patient must agree after consenting to the study to use contraception from enrollment and for at least 13 weeks after taking the final dose of the investigational drug (a period of 90 days [the spermatogenesis cycle] is added to 5-times the elimination half-time of I/O agent. Total abstinence is an acceptable mode of contraception. Exclusion criteria: 1. Unwilling to undergo biopsy retrieval during screening (unless an archival sample taken within 3 months before screening is available) and after the fourth infusion of OB-002 2. Patients who have undergone systemic chemotherapy, radiotherapy, surgery, or hormone therapy <28 days before enrollment, also see exclusion criterion #8. Note: Patients must have recovered from all AEs due to previous therapies to =Grade 1 or baseline. Patients with =Grade 2 neuropathy may be eligible. If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. 3. Patients with a history of CCR5 antagonist therapy (e.g., vicriviroc, maraviroc). 4. Patients with uncontrolled hypertension (systolic blood pressure =150 mmHg or diastolic blood pressure =90 mmHg) with treatment 5. QTc interval greater than 450 msec (males) or 470 msec (females) 6. Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment 7. Patients with a large amount of pleural effusion or ascites requiring more than weekly drainage 8. Patients with a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis. 9. Patients with a =Grade 3 active infection according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 10. Patients with symptomatic brain metastasis (1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to non-central nervous system [CNS] disease) 11. Patients with partial or complete gastrointestinal obstruction 12. Patients with interstitial lung disease requiring treatment with systemic steroids or other agents 13. Patients who test positive for either anti-human immunodeficiency virus type 1 (HIV-1) antibodies, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies with a positive HCV RNA viral load test 14. Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease 15. Patients who require systemic corticosteroids equivalent to =10 mg prednisone (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy) or immunosuppressants, or who have received such a therapy <14 days before enrollment in the present study 16. Patients with a history or findings of =Grade 3 congestive heart failure according to the New York Heart Association functional classification 17. Patients with a seizure disorder who require pharmacotherapy 18. Persistent proteinuria >3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (=Grade 3, NCI CTCAE v5.0) 19. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation 20. Major surgical procedure or significant traumatic injury within 28 days before the start of study medication 21. Non-healing wound, non-healing ulcer, or non-healing bone fracture 22. Patients with evidence or history of any bleeding diathesis, irrespective of severity 23. Any hemorrhage or bleeding event =Grade 3 (NCI CTCAE v 5.0) within 4 weeks prior to the start of the study medication 24. Women who are pregnant or breastfeeding, or with the potential for pregnancy unwilling to undergo contraception 25. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study drug

Study Design


Intervention

Drug:
OB-002
The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Orion Biotechnology Polska Sp. z o.o.

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory: immunogenicity of OB-002 A number of patients developing antidrug antibodies (ADA) and the titers developed in these participants. From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Other Exploratory: evaluation of receptor occupancy (RO) of OB-002 in blood Percent of CCR5 receptors occupied by OB-002 in blood samples are collected from first to fourth infusion (period of 28 days +/- 2 days)
Other Exploratory: evaluation of receptor occupancy (RO) of OB-002 in tumor Percent of CCR5 receptors occupied by OB-002 in tumor biopsies samples are collected from first to fourth infusion (period of 28 days +/- 2 days)
Other Exploratory: preliminary efficacy of OB-002 as monotherapy based on best overall response Objective response rate (ORR): defined as the proportion of patients having best overall response (BOR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the investigator. From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months
Other Exploratory: preliminary efficacy of OB-002 as monotherapy based on complete response Objective response rate (ORR): defined as the proportion of patients having complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the investigator. From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months
Other Exploratory: preliminary efficacy of OB-002 as monotherapy based on partial response Objective response rate (ORR): defined as the proportion of patients having a partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the investigator. From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months
Other Exploratory: preliminary efficacy of OB-002 as monotherapy based on Progression-free survival Progression-free survival (PFS): defined as the time from randomization until objective tumor progression or death, whichever comes first by RECIST v1.1 From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months, assessed up to 12 months
Other Exploratory: evaluation of OB-002 on blood biomarkers (immune cells) Systemic monitoring of circulating immune cells From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Other Exploratory: evaluation of OB-002 on blood biomarkers (cytokines) Systemic monitoring of secreted cytokines. From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Other Exploratory: evaluation of OB-002 on blood biomarkers (chemokines) Systemic monitoring of secreted chemokines. From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Other Exploratory: evaluation of OB-002 on tumor biomarkers (tumor-associated immune cells in TMI) Examination of tumor-associated immune cells in tumor microenvironment From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Other Exploratory: evaluation of OB-002 on blood biomarkers (TCR) Genomic analyses on whole blood/peripheral blood mononuclear cells (PBMC) for T-cell repertoire (TCR) analyses From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Other Exploratory: evaluation of OB-002 on blood biomarkers (ctDNA) Plasma circulating tumor DNA (ctDNA) analysis From first infusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Primary Safety: adverse events Number of patients experiencing adverse events (AEs), serious AEs (SAEs) abnormalities in clinical laboratory tests, vital signs, electrocardiograms (ECGs), and physical exams From date of screening until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Primary Safety: Maximum Tolerated Dose MTD will be defined on the basis of dose-limiting toxicities (DLTs) From date of first infusion with 28 days observation period (+/-3 days)
Secondary (PK) Pharmacokinetics Cmax To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with maximum observed concentration (Cmax) profile of OB-002 in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. samples are collected from first to fourth infusion (period of 28 days +/- 2 days)
Secondary (PK) Pharmacokinetics Tmax To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with time to maximum serum concentration (Tmax) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. samples are collected from first to fourth infusion (period of 28 days +/- 2 days)
Secondary (PK) Pharmacokinetics AUC0-t To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with area under the curve from time 0 to last sampling time (AUC0-t) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. samples are collected from first to fourth infusion (period of 28 days +/- 2 days)
Secondary (PK) Pharmacokinetics AUC0 8 To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with area under the curve from time 0 to infinity (AUC0 8) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. samples are collected from first to fourth infusion (period of 28 days +/- 2 days)
Secondary (PK) Pharmacokinetics t1/2 To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with terminal half-life (t1/2) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. samples are collected from first to fourth infusion (period of 28 days +/- 2 days)
Secondary (PK) Pharmacokinetics Vd To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with the volume of distribution (Vd) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. samples are collected from first to fourth infusion (period of 28 days +/- 2 days)
Secondary (PK) Pharmacokinetics CL To evaluate the multiple-dose pharmacokinetic (PK) profile of OB-002 with clearance (CL) in patients with refractory metastatic colorectal, pancreatic, breast, or urothelial cancer. samples are collected from first to fourth infusion (period of 28 days +/- 2 days)
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2